Novartis AG ADR (NVS)vsAlpha Teknova Inc (TKNO)
NVS
Novartis AG ADR
$148.38
+1.26%
HEALTHCARE · Cap: $289.19B
TKNO
Alpha Teknova Inc
$5.13
-0.97%
HEALTHCARE · Cap: $235.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 135248% more annual revenue ($56.58B vs $41.80M). NVS leads profitability with a 23.9% profit margin vs -41.1%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
TKNO
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.6%
Fair Value
$91.58
Current Price
$148.38
$56.80 premium
Intrinsic value data unavailable for TKNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TKNO
The strongest argument for TKNO centers on Debt/Equity. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : TKNO
The primary concerns for TKNO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while TKNO is a turnaround play — different risk/reward profiles.
TKNO carries more volatility with a beta of 0.63 — expect wider price swings.
TKNO is growing revenue faster at 13.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 28/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Alpha Teknova Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology sector, specializing in the production of vital biological reagents and supplements that cater to life sciences research and biomanufacturing. The company's offerings play a pivotal role in high-demand areas such as vaccine development, cell and gene therapy, and diagnostic testing, underscored by a commitment to quality and exceptional customer service. With a robust biotechnology foundation and a strong focus on innovation, Alpha Teknova is well-equipped to capitalize on growth opportunities in the rapidly evolving life sciences market, positioning itself as a valuable investment for institutional stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?